Amphiphile Vaccines

Potently delivering
vaccines into the lymph nodes

Delivery of immunogens using the Amphiphile platform enables enhanced accumulation in lymph nodes where resident immune cells gather en masse diligently collecting molecular cues to diagnose disease and coordinate protective immune responses. These responses originate with sentinel antigen presenting cell (APCs), specialized immune cells which constantly sample lymph fluid entering the lymph nodes, searching for danger patterns associated with bodily threats including infection or tumors.

Amphiphile vaccines containing information about a patient’s cancer are specifically designed to concentrate together with these sentinel cells in lymph nodes where they can be efficiently internalized to deliver this information directly to the cells which initiate protective immunity. This vaccine-encoded information (antigen and adjuvant) is then transformed by the APC into a set of molecular signals displayed on the cell’s surface for specific recognition by T cells residing in the lymph nodes. This interaction between APCs and T cells in the lymph node represents a potent call to action simultaneously triggering massive expansion of tumor fighting T cells, equipping them with powerful anti-tumor functionality, and programming them for persistent memory to prevent relapse. By more potently delivering vaccines into the lymph nodes, Amphiphiles turn up the volume on this conversation between immune cells with more cells more powerfully communicating to orchestrate more potent, functional, and effective immune responses against cancer.

Amphiphile vaccines accumulate in the lymph nodes, where protective immune cells naturally gather, to potently activate and amplify cancer-killing immune responses.